Colorectal Cancer Screening: Preferences, Past Behavior, and Future Intentions

Mansfield, Carol; Ekwueme, Donatus U.; Tangka, Florence; Brown, Derek S.; Smith, Judith Lee; Guy, Gery P.; Li, Chunyu; Hauber, A. Brett

doi:10.1007/s40271-018-0308-6

Cited by 20 publications

(48 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are just a handful of DCE studies investigating preferences for CRC screening (although none of them focused on how screening and individuals' characteristics impact on CRC screening non-participation) [11,[14][15][16][17][18][19][20]. Several of these DCE studies found that risk reduction of CRC-related mortality is an important screening characteristic for the individual to prefer CRC screening over no screening [11,14,17], which is in line with our findings.…”

Section: Discussionsupporting

confidence: 86%

“…The discrete choice experiment (DCE), a quantitative technique that is commonly used in healthcare research, is a useful method to obtain insights into determinants that have an impact on non-participation for medical interventions [13]. Although several DCE studies exist concerning preferences for population-based faecal screening [11,[14][15][16][17][18][19][20], none of them accounted for scale effects (i.e. how consistent individuals make their choices) and preference heterogeneity (i.e.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

What Factors Influence Non-Participation Most in Colorectal Cancer Screening? A Discrete Choice Experiment

Bekker‐Grob

Donkers

Veldwijk

et al. 2020

Patient

View full text Add to dashboard Cite

Background and Objective Non-participation in colorectal cancer (CRC) screening needs to be decreased to achieve its full potential as a public health strategy. To facilitate successful implementation of CRC screening towards unscreened individuals, this study aimed to quantify the impact of screening and individual characteristics on non-participation in CRC screening. Methods An online discrete choice experiment partly based on qualitative research was used among 406 representatives of the Dutch general population aged 55-75 years. In the discrete choice experiment, respondents were offered a series of choices between CRC screening scenarios that differed on five characteristics: effectiveness of the faecal immunochemical screening test, risk of a false-negative outcome, test frequency, waiting time for faecal immunochemical screening test results and waiting time for a colonoscopy follow-up test. The discrete choice experiment data were analysed in a systematic manner using random-utility-maximisation choice processes with scale and/or preference heterogeneity (based on 15 individual characteristics) and/or random intercepts. Results Screening characteristics proved to influence non-participation in CRC screening (21.7-28.0% non-participation rate), but an individual's characteristics had an even higher impact on CRC screening non-participation (8.4-75.5% nonparticipation rate); particularly the individual's attitude towards CRC screening followed by whether the individual had participated in a cancer screening programme before, the decision style of the individual and the educational level of the individual. Our findings provided a high degree of confidence in the internal-external validity. Conclusions This study showed that although screening characteristics proved to influence non-participation in CRC screening, a respondent's characteristics had a much higher impact on CRC screening non-participation. Policy makers and physicians can use our study insights to improve and tailor their communication plans regarding (CRC) screening for unscreened individuals.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

What Factors Influence Non-Participation Most in Colorectal Cancer Screening? A Discrete Choice Experiment

Bekker‐Grob

Donkers

Veldwijk

et al. 2020

Patient

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the incidence of CRC is still continuously rising among young adult patients with averaged age of under 45 and~25% of patients suffer from systemic metastases, most frequently metastasizing to liver and lung [3], and possess very poor prognosis. Thus, considering the complexity, real-time variability, and intratumoral heterogeneity during CRC occurrence and development, plus individual differences, the current knowledge about predictive biomarkers and prognostic factors of CRC and the treatment options available are still relatively limited, necessitating more forethoughtful study and a better understanding of the underlying mechanisms behind CRC and the development and improvement of the new diagnostic and therapeutic strategies [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

SPT6 recruits SND1 to co‐activate human telomerase reverse transcriptase to promote colon cancer progression

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer (CRC) is continuously rising among young adult patients, necessitating more forethoughtful study and understanding of the mechanisms behind CRC and the development of the new diagnostic and therapeutic strategies. Our research demonstrated that SPT6 synergized with staphylococcal nuclease and Tudor domain containing 1 (SND1) to promote CRC progression by targeting human telomerase reverse transcriptase (hTERT) and put forward that inhibiting SPT6‐SND1‐hTERT axis may create a therapeutic vulnerability in CRC.

show abstract

“…Colorectal cancer (CRC) is one of the most common malignant tumors and the fourth leading cause of cancer-associated mortality worldwide (1). In recent years, despite improvements in precancerous screening (2–4), surgical resection (1), chemotherapy (5), radiotherapy (6) and target therapy (5), patients with CRC still exhibit poor prognosis, particularly patients at advanced stages of the disease (7). Therefore, it is crucial to identify novel therapeutic targets to improve the prognosis of CRC patients.…”

Section: Introductionmentioning

confidence: 99%

Rab23 contributes to the progression of colorectal cancer via protein kinase B and extracellular signal‑regulated kinase signaling pathways

2019

View full text Add to dashboard Cite

The role of Ras-related protein Rab23 in tumors has attracted increasing attention in recent years; however, whether it can function as an oncogenic protein remains under debate, and its role in colorectal cancer (CRC) is currently unknown. In the present study, high expression of Rab23 in CRC tissues was confirmed using immunohistochemistry, and high expression of Rab23 in CRC cells (SW1116 and HT29) was confirmed using reverse transcription-polymerase chain reaction and western blot analysis. A positive association of Rab23 with tumor size and advanced clinical stage was confirmed by χ 2 analysis. In addition, the positive association of Rab23 with poor disease-free survival was confirmed by survival analysis. Cell experiments further demonstrated that overexpression of Rab23 increased the expression of the proliferation marker Ki-67 and the proliferative ability in SW1116 and HT29 cells. Molecular mechanism research revealed that the extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) signaling pathways contributed to the high expression of Ki-67 and increased the proliferative ability induced by Rab23 in CRC cells. In conclusion, the study confirmed the high expression of Rab23 in CRC, and its positive association with CRC progression and poor prognosis. Furthermore, the data demonstrated that Rab23 increased the proliferation of CRC cells via the ERK and AKT signaling pathways. These results suggest that Rab23 may be used as a protein for diagnosis and prognosis prediction in patients with CRC, and is proposed to be a novel therapeutic target for improving the patient outcome.

show abstract

Colorectal Cancer Screening: Preferences, Past Behavior, and Future Intentions

Cited by 20 publications

References 24 publications

What Factors Influence Non-Participation Most in Colorectal Cancer Screening? A Discrete Choice Experiment

What Factors Influence Non-Participation Most in Colorectal Cancer Screening? A Discrete Choice Experiment

SPT6 recruits SND1 to co‐activate human telomerase reverse transcriptase to promote colon cancer progression

Rab23 contributes to the progression of colorectal cancer via protein kinase B and extracellular signal‑regulated kinase signaling pathways

Contact Info

Product

Resources

About